Skip to content

A Study on the Role of Blood-Related Imbalance in Patients with Vicharchika (Eczema)

Nidanatmaka Study on Raktavaha Srotodushti with special reference to Vicharchika - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/105728
Enrollment
60
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20-L30- Dermatitis and eczema

Interventions

Intervention1: Nil: Nil

Sponsors

Government Ayurvedic College and Hospital, Kadamkuan, Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. On the basis of age group (15-70yr) 2. Patient of both sexes will be taken for study 3. The patient sign and symptoms should be based on both ayurvedic as well as modern

Exclusion criteria

Exclusion criteria: 1. Age less than 15 years and above 70 years. 2. Patient who have any uncontrolled systematic disease.

Design outcomes

Primary

MeasureTime frame
Assessment of clinical features of Raktavaha Srotodushti in patients diagnosed with Vicharchika using predefined Ayurvedic diagnostic criteria.Timepoint: At the time of patient assessment / baseline

Secondary

MeasureTime frame
1. Assessment of severity of symptoms of Vicharchika such as itching (Kandu), discoloration (Vaivarnya), eruption (Pidika), and discharge (Srava) using a grading scale. 2. Correlation between features of Raktavaha Srotodushti and clinical manifestations of Vicharchika. 3. Distribution of demographic factors (age, sex, duration of disease) in patients suffering from Vicharchika.Timepoint: At the time of patient assessment / baseline

Countries

India

Contacts

Public ContactDr Amarendra Kumar Singh

Government Ayurvedic College and Hospital, Kadamkuan, Patna

singh.amrendra70@yahoo.co.in9931230820

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026